Genesis Therapeutics
PrivateLast Round
Series B
Extension
Nov 13, 2024
Est. Valuation
$144M
Total Funding Raised
$304.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Genesis Therapeutics operates in Healthcare & Life Sciences and is based in Burlingame, California. Its latest recorded funding round was a Series B Extension round in November 2024.
Genesis Therapeutics is a biotechnology company that utilizes a proprietary AI platform, GEMS, to discover and develop novel small-molecule drugs for severe and debilitating diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genesis Therapeutics Comparables
Compare Genesis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terray Therapeutics | 87% | |
| PostEra | 86% | |
| Chai Discovery | 86% |
For institutional investors. Book with your work email.
Genesis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Nov 13, 2024 | ||||
| Series B | Aug 21, 2023 | ||||
| Series A | Dec 2, 2020 | ||||
| Seed | Nov 21, 2019 |
For institutional investors. Book with your work email.
Genesis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Series B, Seed |
| Fidelity Management & Research Company | Series B |
| JAZZ Venture Partners | Series A |
| Propagator Ventures | Series A |
| Open Field Capital | Series A |
| T. Rowe Price | Series B, Series A |
| Ulu Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 177, 104% of headcount.
- Nov 13, 2024
NVentures led the latest VC Round.
For institutional investors. Book with your work email.
Genesis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genesis Therapeutics's valuation, stock price, and market status.
Is Genesis Therapeutics a public or private company?
Genesis Therapeutics is a private company.
What is the current stock price of Genesis Therapeutics?
Genesis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Genesis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genesis Therapeutics worth (valuation)?
Genesis Therapeutics's valuation is estimated at $144.0M based on funding round data.
Can I buy Genesis Therapeutics stock?
Genesis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genesis Therapeutics's last funding round?
Genesis Therapeutics's most recent funding round was Series B Extension on November 13, 2024.
Who are the main investors in Genesis Therapeutics?
Key investors in Genesis Therapeutics include Andreessen Horowitz, NVentures, Rock Springs Capital, Radical Ventures.
Will Genesis Therapeutics IPO soon?
No public IPO plans have been announced for Genesis Therapeutics.
How can I track Genesis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Genesis Therapeutics's shares on secondary markets.